Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TransMedics Group, Inc.TMDX · Entity 4261 | Director · President & CEO | July 10, 2026 | July 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TransMedics Group, Inc.
Report date July 10, 2026 · Filed July 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 171,093 |
Reported balance
After 2026-07-10 transaction · row 1
1 source rowRow 1 · 2026-07-10 · Grant · Acquired 49,669 · Balance 171,093 F1: Consists of 49,669 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.23 · Expires 2036-07-10 | Direct | 112,984 |
Reported balance
After 2026-07-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-10 · Grant · Acquired 112,984 · Balance 112,984 F3: The option vests at a rate of 2.0833% of the total number of shares subject to the option each month following April 10, 2026 until the option is fully vested on April 10, 2030, subject to continued service. |
| Common StockSEC Table I · non-derivative | IndirectBy the Waleed H. Hassanein Revocable Trust | 345,009 |
Reported balance
Holding disclosure · report date 2026-07-10 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 345,009 F2: Reflects a prior transfer of 150,000 shares of the Issuer's common stock from the Waleed H. Hassanein Revocable Trust to the Hassanein 2026 Qualified Annuity Trust. The transfer constituted only a change in the form of beneficial ownership and was exempt under Rule 16a-13 of the Securities Exchange Act of 1934, as amended. |
| Common StockSEC Table I · non-derivative | IndirectBy the Hassanein 2026 Qualified Annuity Trust | 150,000 |
Reported balance
Holding disclosure · report date 2026-07-10 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 150,000 F2: Reflects a prior transfer of 150,000 shares of the Issuer's common stock from the Waleed H. Hassanein Revocable Trust to the Hassanein 2026 Qualified Annuity Trust. The transfer constituted only a change in the form of beneficial ownership and was exempt under Rule 16a-13 of the Securities Exchange Act of 1934, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of 49,669 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F2: Reflects a prior transfer of 150,000 shares of the Issuer's common stock from the Waleed H. Hassanein Revocable Trust to the Hassanein 2026 Qualified Annuity Trust. The transfer constituted only a change in the form of beneficial ownership and was exempt under Rule 16a-13 of the Securities Exchange Act of 1934, as amended.
F3: The option vests at a rate of 2.0833% of the total number of shares subject to the option each month following April 10, 2026 until the option is fully vested on April 10, 2030, subject to continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 10, 2026 Filed Jul 15, 2026 01:28 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantStock Option (Right to Buy) · Derivative | 112,984 | $0.00 Strike: $71.23 | $0.00 |
DisclosureSEC source: 0001193125-26-303704 · ownership.xml · derivative · entry 4 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,984 Underlying: Common Stock · 112,984 shares Expires 2036-07-10 F3 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares subject to the option each month following April 10, 2026 until the option is fully vested on April 10, 2030, subject to continued service. Read SEC document |
| July 10, 2026 Filed Jul 15, 2026 01:28 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantCommon Stock | 49,669 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-303704 · ownership.xml · nonDerivative · entry 1 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,093 F1 · kind: Consists of 49,669 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 21:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | PurchaseCommon Stock | 8,775 | $114.00 | $1,000,350.00 |
DisclosureSEC source: 0001193125-25-286229 · ownership.xml · nonDerivative · entry 1 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By the Waleed H. Hassanein Revocable Trust Disclosed balance after: 495,009 Read SEC document |
| August 07, 2025 Filed Aug 8, 2025 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | PurchaseCommon Stock | 1,858 | $116.85 | $217,107.30 |
DisclosureSEC source: 0000950170-25-105907 · ownership.xml · nonDerivative · entry 3 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By the Waleed H. Hassanein Revocable Trust Disclosed balance after: 486,234 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $116.62 to $117.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| August 07, 2025 Filed Aug 8, 2025 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | PurchaseCommon Stock | 6,617 | $116.08 | $768,101.36 |
DisclosureSEC source: 0000950170-25-105907 · ownership.xml · nonDerivative · entry 2 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By the Waleed H. Hassanein Revocable Trust Disclosed balance after: 484,376 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $115.60 to $116.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | PurchaseCommon Stock | 8,400 | $118.68 | $996,912.00 |
DisclosureSEC source: 0000950170-25-105907 · ownership.xml · nonDerivative · entry 1 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By the Waleed H. Hassanein Revocable Trust Disclosed balance after: 477,759 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $118.50 to $118.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| February 25, 2025 Filed Feb 26, 2025 23:16 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantStock Option (Right to Buy) · Derivative | 90,185 | $0.00 Strike: $73.00 | $0.00 |
DisclosureSEC source: 0000950170-25-028069 · ownership.xml · derivative · entry 3 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,185 Underlying: Common Stock · 90,185 shares Expires 2035-02-25 F2 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares subject to the option each month following February 25, 2025 until the option is fully vested on February 25, 2029, subject to continued service. Read SEC document |
| February 25, 2025 Filed Feb 26, 2025 23:16 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantCommon Stock | 59,781 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-028069 · ownership.xml · nonDerivative · entry 1 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,424 F1 · shares: Consists of 59,781 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| October 15, 2024 Filed Oct 17, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,625 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0000950170-24-115332 · ownership.xml · derivative · entry 7 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,250 Underlying: Common Stock · 8,625 shares Expires 2032-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 22, 2026. Read SEC document |
| October 15, 2024 Filed Oct 17, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 300 | $135.04 | $40,512.00 |
DisclosureSEC source: 0000950170-24-115332 · ownership.xml · nonDerivative · entry 5 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,643 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $134.63 to $135.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 15, 2024 Filed Oct 17, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 1,200 | $134.23 | $161,076.00 |
DisclosureSEC source: 0000950170-24-115332 · ownership.xml · nonDerivative · entry 4 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,943 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $133.57 to $134.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 15, 2024 Filed Oct 17, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 3,518 | $132.82 | $467,260.76 |
DisclosureSEC source: 0000950170-24-115332 · ownership.xml · nonDerivative · entry 3 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,143 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $132.34 to $133.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 15, 2024 Filed Oct 17, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 3,607 | $131.91 | $475,799.37 |
DisclosureSEC source: 0000950170-24-115332 · ownership.xml · nonDerivative · entry 2 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,661 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $131.29 to $132.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 15, 2024 Filed Oct 17, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 8,625 | $13.28 | $114,540.00 |
DisclosureSEC source: 0000950170-24-115332 · ownership.xml · nonDerivative · entry 1 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,268 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 23:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,625 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0000950170-24-107497 · ownership.xml · derivative · entry 9 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,875 Underlying: Common Stock · 8,625 shares Expires 2032-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option is fully vested. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 23:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 626 | $156.48 | $97,956.48 |
DisclosureSEC source: 0000950170-24-107497 · ownership.xml · nonDerivative · entry 7 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,643 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $156.19 to $157.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 23:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 688 | $155.65 | $107,087.20 |
DisclosureSEC source: 0000950170-24-107497 · ownership.xml · nonDerivative · entry 6 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,269 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $155.15 to $156.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 23:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 1,383 | $154.16 | $213,203.28 |
DisclosureSEC source: 0000950170-24-107497 · ownership.xml · nonDerivative · entry 5 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,957 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $153.92 to $154.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 23:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 3,155 | $153.32 | $483,724.60 |
DisclosureSEC source: 0000950170-24-107497 · ownership.xml · nonDerivative · entry 4 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,340 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $152.88 to $153.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 23:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 1,865 | $152.30 | $284,039.50 |
DisclosureSEC source: 0000950170-24-107497 · ownership.xml · nonDerivative · entry 3 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,495 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $151.83 to $152.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 23:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 908 | $151.10 | $137,198.80 |
DisclosureSEC source: 0000950170-24-107497 · ownership.xml · nonDerivative · entry 2 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,360 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $150.64 to $151.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 23:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 8,625 | $13.28 | $114,540.00 |
DisclosureSEC source: 0000950170-24-107497 · ownership.xml · nonDerivative · entry 1 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,268 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| August 22, 2024 Filed Aug 23, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $16.14 | $0.00 |
DisclosureSEC source: 0000950170-24-100208 · ownership.xml · derivative · entry 7 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,000 Underlying: Common Stock · 25,000 shares Expires 2030-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| August 22, 2024 Filed Aug 23, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 25,000 | $175.00 | $4,375,000.00 |
DisclosureSEC source: 0000950170-24-100208 · ownership.xml · nonDerivative · entry 4 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,643 Read SEC document |
| August 22, 2024 Filed Aug 23, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 25,000 | $16.14 | $403,500.00 |
DisclosureSEC source: 0000950170-24-100208 · ownership.xml · nonDerivative · entry 3 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,643 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000950170-24-100208 · ownership.xml · derivative · entry 6 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,714 Underlying: Common Stock · 20,000 shares Expires 2029-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 20,000 | $171.03 | $3,420,600.00 |
DisclosureSEC source: 0000950170-24-100208 · ownership.xml · nonDerivative · entry 2 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,643 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $171.00 to $171.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 20,000 | $16.00 | $320,000.00 |
DisclosureSEC source: 0000950170-24-100208 · ownership.xml · nonDerivative · entry 1 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,643 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,625 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0000950170-24-098574 · ownership.xml · derivative · entry 10 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,500 Underlying: Common Stock · 8,625 shares Expires 2032-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F9 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 22, 2026. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 205 | $171.86 | $35,231.30 |
DisclosureSEC source: 0000950170-24-098574 · ownership.xml · nonDerivative · entry 8 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,643 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F8 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $171.80 to $171.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 1,018 | $171.42 | $174,505.56 |
DisclosureSEC source: 0000950170-24-098574 · ownership.xml · nonDerivative · entry 7 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,848 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $170.79 to $171.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 4,526 | $170.21 | $770,370.46 |
DisclosureSEC source: 0000950170-24-098574 · ownership.xml · nonDerivative · entry 6 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,866 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $169.77 to $170.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 1,376 | $169.39 | $233,080.64 |
DisclosureSEC source: 0000950170-24-098574 · ownership.xml · nonDerivative · entry 5 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,392 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $168.77 to $169.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 500 | $168.17 | $84,085.00 |
DisclosureSEC source: 0000950170-24-098574 · ownership.xml · nonDerivative · entry 4 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,768 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $167.77 to $168.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 700 | $167.24 | $117,068.00 |
DisclosureSEC source: 0000950170-24-098574 · ownership.xml · nonDerivative · entry 3 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,268 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $166.77 to $167.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 300 | $165.26 | $49,578.00 |
DisclosureSEC source: 0000950170-24-098574 · ownership.xml · nonDerivative · entry 2 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,968 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $164.85 to $165.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 8,625 | $13.28 | $114,540.00 |
DisclosureSEC source: 0000950170-24-098574 · ownership.xml · nonDerivative · entry 1 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,268 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,625 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0000950170-24-084297 · ownership.xml · derivative · entry 8 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,125 Underlying: Common Stock · 8,625 shares Expires 2032-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F7 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 22, 2026. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 300 | $147.28 | $44,184.00 |
DisclosureSEC source: 0000950170-24-084297 · ownership.xml · nonDerivative · entry 6 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,643 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $147.02 to $147.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 2,342 | $146.39 | $342,845.38 |
DisclosureSEC source: 0000950170-24-084297 · ownership.xml · nonDerivative · entry 5 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,943 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $146.00 to $146.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 2,046 | $145.54 | $297,774.84 |
DisclosureSEC source: 0000950170-24-084297 · ownership.xml · nonDerivative · entry 4 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,285 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $145.07 to $145.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 2,540 | $144.34 | $366,623.60 |
DisclosureSEC source: 0000950170-24-084297 · ownership.xml · nonDerivative · entry 3 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,331 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $144.03 to $144.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 1,397 | $143.61 | $200,623.17 |
DisclosureSEC source: 0000950170-24-084297 · ownership.xml · nonDerivative · entry 2 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,871 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $143.00 to $143.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 8,625 | $13.28 | $114,540.00 |
DisclosureSEC source: 0000950170-24-084297 · ownership.xml · nonDerivative · entry 1 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,268 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,625 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0000950170-24-074284 · ownership.xml · derivative · entry 8 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,750 Underlying: Common Stock · 8,625 shares Expires 2032-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F7 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 22, 2026. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 100 | $144.52 | $14,452.00 |
DisclosureSEC source: 0000950170-24-074284 · ownership.xml · nonDerivative · entry 6 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,643 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $144.51 to $144.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 400 | $143.65 | $57,460.00 |
DisclosureSEC source: 0000950170-24-074284 · ownership.xml · nonDerivative · entry 5 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,743 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $143.30 to $144.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 2,675 | $142.68 | $381,669.00 |
DisclosureSEC source: 0000950170-24-074284 · ownership.xml · nonDerivative · entry 4 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,143 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $142.12 to $143.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 3,836 | $141.62 | $543,254.32 |
DisclosureSEC source: 0000950170-24-074284 · ownership.xml · nonDerivative · entry 3 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,818 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $141.10 to $142.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 1,614 | $140.42 | $226,637.88 |
DisclosureSEC source: 0000950170-24-074284 · ownership.xml · nonDerivative · entry 2 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,654 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $139.92 to $140.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.